
Can T45 Labs use its cross-country connections to bypass MedTech’s early-stage funding shortage?
11/15/24 • 55 min
Previous Episode

Andy Pierce shares how Stryker is “fighting on its front foot” through R&D and aggressive M&A
In this StrykerTalks episode, Andy Pierce, Group President of MedSurg and Neurotechnology at Stryker, shares his insights on the company’s commitment to innovation, growth, and patient-centered care. Pierce reflects on his 29-year journey with Stryker, highlighting the high-performance culture shaped by entrepreneurial spirit, growth targets, and strategic acquisitions. He discusses how Stryker’s decentralized structure supports quick, localized decision-making while fostering collaboration across its business units. The conversation also explores the company's M&A strategy, focusing on acquisitions that bring de-risked, high-impact technologies that align with Stryker’s long-term goals. Pierce provides an inside look at Stryker's engagement with the soft tissue robotics space, its approach to balancing internal and external innovation, and the proactive steps Stryker takes to address healthcare staffing shortages with technology. Thank you to Vantedge Medical for sponsoring this episode. To learn more about how Vantedge Medical works with medical device companies, visit www.vantedgemedical.com Thank you for listening to the StrykerTalks Podcast. Subscribe to the DeviceTalks Podcast Network so you don’t miss a future episode.
Next Episode

Edwards' Larry Wood discusses TAVR evolution, new clinical paradigms, and addressing treatment gaps
In this episode of Structural Heart Talks, Larry Wood, Corporate VP and Group President, Transcatheter Aortic Valve Replacement and Surgical Structural Heart at Edwards Lifesciences, discusses the transformative journey of transcatheter aortic valve replacement (TAVR) and the SAPIEN valve. Wood reflects on the innovation that enables minimally invasive heart valve replacement, which has become the standard of care for severe aortic stenosis and offers patients faster recovery and greater independence. The conversation explores Edwards’ efforts to expand access to TAVR, emphasizing the importance of reducing undertreatment and addressing outdated clinical guidelines that delay intervention. Wood also highlights findings from the recent EARLY TAVR study, which challenges long-standing paradigms and advocates for changes to the guidelines to allow earlier treatment of aortic stenosis before symptoms appear. Tune in to the 2021 episode of DeviceTalks Weekly where Host, Tom Salemi visits with Larry Wood to discuss the "Complete History of the SAPIEN TAVR," here: https://www.devicetalks.com/the-complete-history-of-the-sapien-tavr-from-pvts-emerging-idea-to-edwards-lifesciences-success/ Thank you to Confluent Medical Technologies for sponsoring this episode of Structural Heart Talks. To learn more about how Confluent Medical supports medical device companies, visit: www.confluentmedical.com. Thank you for listening to the Structural Heart Talks podcast. Tune in and subscribe to the DeviceTalks Podcast Network wherever you get your podcasts and follow youtube.com/@DeviceTalks or the Structural Heart Talks on YouTube Podcasts to ensure you never miss an episode.
If you like this episode you’ll love
Episode Comments
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/devicetalks-podcast-network-310096/can-t45-labs-use-its-cross-country-connections-to-bypass-medtechs-earl-78347881"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to can t45 labs use its cross-country connections to bypass medtech’s early-stage funding shortage? on goodpods" style="width: 225px" /> </a>
Copy